Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetics of Methemoglobin Concentration in Healthy Subjects Exposed to High Dose Inhaled Nitric Oxide
NCT05612074Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2023
- Primary completion
- Nov 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nitric oxide, sponsored by Massachusetts General Hospital. Primary endpoint: Methemoglobin kinetics at 7 days. Started Oct 2023; status: active, not recruiting.
02
Drugs
nitric oxide
Beyond the preview
Go deeper on NCT05612074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05612074.